RE:ImmunityBio Snags $320M Royalty Deal Ahead of FDA DecisionAs written, the solution sounds real good and effective (as long ss BCG is not in short supply). And just 5 more months before approval. I bought some options.
In the meantime for TLT, this new email from their BOD chair (assuming it's true) states they're awaiting data on 6 more patients. So in addition to requiring extended survival data on CR patients and central lab validation of all data, wonder if this 6-patient dataset will be the latest delay wrinkle quietly added to the pre-BTD application. I'm resigned to it at this point if it becomes true. I just see no way around another raise in less than 4-6 weeks. No JV or non dilutive options without first showing you have a winner. Hardly anyone is trading this stock in the US, so it'll have to be Canadian wallets again.